Study to Assess the Effect of Zinc in Atorvastatin Treated Hyperlipidemic Patients
Status:
Recruiting
Trial end date:
2022-07-10
Target enrollment:
Participant gender:
Summary
This study was 8 weeks randomized, double-blind, placebo-controlled trial to assess the
effect of zinc in Atorvastatin treated hyperlipidemic 92 patients. Participants were assessed
at baseline, and 8 weeks. Subjects were randomized to receive either atorvastatin+placebo in
one arm or atorvastatin +zinc 30mg tablet in another arm daily for 8 weeks. The outcome was
the measure of fasting lipid profile, sgpt, serum creatinine at baseline and after 8 weeks
following the intervention.
Phase:
Phase 2
Details
Lead Sponsor:
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh